Year All20242023202220212020201920182017 Inozyme Pharma to Present at Upcoming Investor Conferences Nov 11, 2024 Inozyme Pharma Reports Third Quarter 2024 Financial Results and Provides Business Highlights Nov 05, 2024 Inozyme Pharma Announces Positive Interim Data from Phase 1 SEAPORT 1 Trial of INZ-701 Oct 24, 2024 Inozyme Pharma Announces Presentation of Interim Data from Phase 1 SEAPORT 1 Trial at the Upcoming American Society of Nephrology (ASN) Kidney Week 2024 Oct 17, 2024 Inozyme Pharma Announces Appointment of Biopharmaceutical Commercial Leader Erik Harris to its Board of Directors Oct 07, 2024 Inozyme Pharma Presents New Data at the American Society for Bone and Mineral Research (ASBMR) 2024 Annual Meeting Sep 26, 2024 Inozyme Pharma to Participate at the 2024 Wells Fargo Healthcare Conference Aug 29, 2024 Inozyme Pharma Reports Second Quarter 2024 Financial Results and Provides Business Highlights Aug 06, 2024 Inozyme Pharma Publishes Preclinical Data Supporting INZ-701 as a Potential Therapy for a Broad Range of Serious Rare Diseases Impacting Bone Health and Blood Vessel Function Jul 25, 2024 Inozyme Pharma Announces FDA Fast Track Designation for INZ-701 in ABCC6 Deficiency Jul 02, 2024
Year All20242023202220212020201920182017 Inozyme Pharma to Present at Upcoming Investor Conferences Nov 11, 2024 Inozyme Pharma Reports Third Quarter 2024 Financial Results and Provides Business Highlights Nov 05, 2024 Inozyme Pharma Announces Positive Interim Data from Phase 1 SEAPORT 1 Trial of INZ-701 Oct 24, 2024 Inozyme Pharma Announces Presentation of Interim Data from Phase 1 SEAPORT 1 Trial at the Upcoming American Society of Nephrology (ASN) Kidney Week 2024 Oct 17, 2024 Inozyme Pharma Announces Appointment of Biopharmaceutical Commercial Leader Erik Harris to its Board of Directors Oct 07, 2024 Inozyme Pharma Presents New Data at the American Society for Bone and Mineral Research (ASBMR) 2024 Annual Meeting Sep 26, 2024 Inozyme Pharma to Participate at the 2024 Wells Fargo Healthcare Conference Aug 29, 2024 Inozyme Pharma Reports Second Quarter 2024 Financial Results and Provides Business Highlights Aug 06, 2024 Inozyme Pharma Publishes Preclinical Data Supporting INZ-701 as a Potential Therapy for a Broad Range of Serious Rare Diseases Impacting Bone Health and Blood Vessel Function Jul 25, 2024 Inozyme Pharma Announces FDA Fast Track Designation for INZ-701 in ABCC6 Deficiency Jul 02, 2024
Inozyme Pharma Reports Third Quarter 2024 Financial Results and Provides Business Highlights Nov 05, 2024
Inozyme Pharma Announces Presentation of Interim Data from Phase 1 SEAPORT 1 Trial at the Upcoming American Society of Nephrology (ASN) Kidney Week 2024 Oct 17, 2024
Inozyme Pharma Announces Appointment of Biopharmaceutical Commercial Leader Erik Harris to its Board of Directors Oct 07, 2024
Inozyme Pharma Presents New Data at the American Society for Bone and Mineral Research (ASBMR) 2024 Annual Meeting Sep 26, 2024
Inozyme Pharma Reports Second Quarter 2024 Financial Results and Provides Business Highlights Aug 06, 2024
Inozyme Pharma Publishes Preclinical Data Supporting INZ-701 as a Potential Therapy for a Broad Range of Serious Rare Diseases Impacting Bone Health and Blood Vessel Function Jul 25, 2024